The company said total revenues for Q1 2025 were $11.2 billion, down 6% (down 4% Ex-FX). Growth Portfolio revenues rose 16% to $5.6 billion, and Legacy Portfolio revenues fell 20% to $5.6 billion.

1. 01

   The company said total revenues for Q1 2025 were $11.2 billion, down 6% (down 4% Ex-FX). Growth Portfolio revenues rose 16% to $5.6 billion, and Legacy Portfolio revenues fell 20% to $5.6 billion.

2. 02

   Bristol Myers Squibb said GAAP EPS for Q1 was $1.20 and non-GAAP EPS was $1.80. GAAP EPS for the same period last year was $(5.89), and non-GAAP EPS was $(4.40). The company said the effective tax rate for the same period last year was $12.1 billion, which was affected by the one-time non-tax-deductible charge for the Karuna acquisition.

3. 03

   The company said it raised its full-year revenue outlook to approximately $45.8 billion to $46.8 billion from the prior approximately $45.5 billion, and set its non-GAAP EPS range at $6.70 to $7.00. The company said the outlook reflects the impact of current tariffs but does not reflect potential pharmaceutical sector tariffs.

4. 04

   The company reported cash and cash equivalents and marketable debt securities of $12,126 million as of March 31, 2025, and a net debt position of $(37,584) million. The net debt position was $(38,470) million as of December 31, 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.